TELA (TELA Bio) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TELA TELA Bio Inc TELA
52 GF Score
Price $0.74
GF Value $1.65
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is TELA Bio 5-Year Yield-on-Cost %?

TELA Bio TELA +0.71% 52 5-Year Yield-on-Cost % is 0.00 as of Aug. 03, 2026. GuruFocus rates TELA with a GF Score™ of 52/100 and a GF Value™ of $1.65 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 318 Medical Devices & Instruments companies, TELA Bio ranks worse than 314465.09% on this metric.

TELA Bio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for TELA Bio's 5-Year Yield-on-Cost % or its related term are showing as below:



TELA's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.435
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

TELA Bio  (NAS:TELA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


TELA Bio 5-Year Yield-on-Cost % Related Terms


TELA vs NSPR, RDGL, BDMD: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, TELA Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TELA Bio 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where TELA Bio's 5-Year Yield-on-Cost % falls into.


TELA
52GF Score
TELA Bio Inc TELA
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TELA Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of TELA Bio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
TELA Bio (TELA) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #999999 out of 318 companies in the Medical Devices & Instruments industry.
Is TELA Bio's 5-Year Yield-on-Cost % too high?
TELA Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, TELA Bio ranks #999999 out of 318 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TELA Bio has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's 5-Year Yield-on-Cost % compare to NSPR and RDGL?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #999999 out of 318 companies for 5-Year Yield-on-Cost %. This places TELA Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TELA Bio and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TELA Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.65, compared to a current price of $0.74 — trading 55.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. TELA Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TELA Bio (TELA), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TELA Bio (TELA) Overvalued in 2026?

Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued. The current stock price of $0.74 is trading 55.2% below its estimated GF Value™ of $1.65. GuruFocus considers TELA Bio to be Possible Value Trap.

Key valuation signals for TELA:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $1.65 vs. price of $0.74 (55.2% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TELA Bio Business Description

Address 1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
52GF Score

Get the complete analysis for TELA

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price
$1.65
GF Value